Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-01

Clinical Trial Update: A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma [Phase 3]

View source ↗

Summary

Phase 3 non-inferiority trial comparing Foraseq (budesonide/formoterol) to Alenia in asthma has completed with results posted on 2025-05-01.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alenia (budesonide/formoterol)
  • Foraseq

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2025-05-01